Guangzhou Boji Medical and Biotechnological Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 13.78%

Guangzhou Boji Medical and Biotechnological Co Ltd (300404) has an Asset Resilience Ratio of 13.78% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥230.34 Million
≈ $33.71 Million USD Cash + Short-term Investments

Total Assets

CN¥1.67 Billion
≈ $244.53 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Guangzhou Boji Medical and Biotechnological Co Ltd's Asset Resilience Ratio has changed over time. Check 300404 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Guangzhou Boji Medical and Biotechnological Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Guangzhou Boji Medical and Biotechnologi worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥230.34 Million 13.78%
Total Liquid Assets CN¥230.34 Million 13.78%

Asset Resilience Insights

  • Moderate Liquidity: Guangzhou Boji Medical and Biotechnological Co Ltd has 13.78% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Guangzhou Boji Medical and Biotechnological Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guangzhou Boji Medical and Biotechnological Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Biotechnology 46.79%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 63.47%
Chengdu Kanghua Biological Products
SHE:300841
Biotechnology 1.19%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%

Annual Asset Resilience Ratio for Guangzhou Boji Medical and Biotechnological Co Ltd (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Guangzhou Boji Medical and Biotechnological Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 3.40% CN¥55.37 Million
≈ $8.10 Million
CN¥1.63 Billion
≈ $238.44 Million
+1.77pp
2024-12-31 1.63% CN¥23.68 Million
≈ $3.46 Million
CN¥1.45 Billion
≈ $212.27 Million
+1.12pp
2023-12-31 0.52% CN¥7.38 Million
≈ $1.08 Million
CN¥1.43 Billion
≈ $209.10 Million
-3.09pp
2022-12-31 3.61% CN¥45.69 Million
≈ $6.69 Million
CN¥1.27 Billion
≈ $185.17 Million
+1.85pp
2021-12-31 1.76% CN¥20.00 Million
≈ $2.93 Million
CN¥1.14 Billion
≈ $166.56 Million
-6.41pp
2018-12-31 8.17% CN¥49.50 Million
≈ $7.24 Million
CN¥606.02 Million
≈ $88.68 Million
+3.13pp
2017-12-31 5.04% CN¥28.96 Million
≈ $4.24 Million
CN¥574.72 Million
≈ $84.10 Million
-6.53pp
2016-12-31 11.56% CN¥60.00 Million
≈ $8.78 Million
CN¥518.85 Million
≈ $75.92 Million
-18.20pp
2015-12-31 29.76% CN¥154.80 Million
≈ $22.65 Million
CN¥520.15 Million
≈ $76.11 Million
--
pp = percentage points

About Guangzhou Boji Medical and Biotechnological Co Ltd

SHE:300404 China Biotechnology
Market Cap
$520.44 Million
CN¥3.56 Billion CNY
Market Cap Rank
#11875 Global
#3366 in China
Share Price
CN¥9.22
Change (1 day)
+0.77%
52-Week Range
CN¥8.29 - CN¥13.15
All Time High
CN¥297.35
About

Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. It offers pre-clinical research, clinical research, and other consulting services. The company also provides clinical drug production, pilot test scale-up, process verification batch … Read more